Logo XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. separator study
Show results for
Products
Services
Training
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Separator Study Articles & Analysis

91 news found

HARMO conference papers & other recent co-author publications

HARMO conference papers & other recent co-author publications

This work contributes to Environment Agency research on the thermal transport of air pollution from regulated industries.RIVM presented results from a study comparing eight widely used atmospheric dispersion and deposition models, including ADMS, against local-scale ammonia and NOx deposition. CERC contributed to this study, which highlighted variability and ...

ByCambridge Environmental Research Consultants (CERC)


Hiden Analytical QGA 2.0 Gas Analyser: Applications

Hiden Analytical QGA 2.0 Gas Analyser: Applications

Hiden Analytical proud to showcase the diverse applications of the QGA 2.0, its next-generation gas analyser. This advanced system is tailored for a wide range of applications, demonstrating its versatility and precision in various research and industrial ...

ByHiden Analytical Ltd.


Creative Proteomics Boosts Your Project with Unknown Metabolite Identification Services

Creative Proteomics Boosts Your Project with Unknown Metabolite Identification Services

Creative Proteomics is an integrated CRO company committed to providing a full range of services in order to support various proteome research projects, from the identification of single proteins to large-scale proteomic studies. Recently, Creative Proteomics has developed a new strategy for identifying unknown metabolites by combining NMR, LC-MS/MS, as well as rule- and ...

ByCreative Proteomics


ComEd Launches Three New Studies to Help Design the Power Grid to Support State's Clean Energy Goals

ComEd Launches Three New Studies to Help Design the Power Grid to Support State's Clean Energy Goals

These studies complement the comprehensive Climate Risk and Adaptation Study announced last week by ComEd and the U.S. ...

BySmart Grid Observer


Neurolief’s Digital Therapeutics Neuromodulation System May Challenge Medication Therapies for the Treatment of Migraine

Neurolief’s Digital Therapeutics Neuromodulation System May Challenge Medication Therapies for the Treatment of Migraine

“The results of this study are extremely promising”, said Daniel Oved, MD, Ramat-Aviv Medical Center, Tel Aviv, Israel, who was the principal investigator of the study. ...

ByNeurolief Ltd.


Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update

Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update

Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged 18 to 64 for the Prevention of Invasive Pneumococcal Disease and Pneumonia Announcement of Topline Safety, Tolerability and Immunogenicity Results from Both the Phase 1 and 2 Portions of the VAX-24 Phase 1/2 Study Expected by ...

ByVaxcyte, Inc.


Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

REDIRECT is a phase 2, registration-directed study of AFM13 monotherapy in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL). ...

ByAffimed GmbH


AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

” Data collected from six gene therapy study groups in mice show: Stable engraftment up to eight months after gene therapy, with median vector copy numbers (VCN) between 1.9 and 3.6 per diploid genome (n=9-13 per group) in bone marrow among all study groups. ...

ByTectonic Therapeutic, Inc.


Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

These data support the rationale for AFM24 as monotherapy and the two combinations that are currently under way in separate phase 1/2a studies – with autologous NK cell therapy and with immune checkpoint inhibition. ...

ByAffimed GmbH


Real-World Evidence Confirms Immediate and Ongoing Performance of the t:slim X2 Insulin Pump with Control-IQ Technology in Children and Adults

Real-World Evidence Confirms Immediate and Ongoing Performance of the t:slim X2 Insulin Pump with Control-IQ Technology in Children and Adults

Control-IQ Observational (CLIO) Longitudinal Study Results at 9 Months This analysis included data from 1,913 participants from the CLIO Study who had at least 9 months experience using Control-IQ technology, and examined relationships between glycemic metrics, participants’ age, and previous insulin delivery method. ...

ByTandem Diabetes Care, Inc.


UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

” The proof-of-concept Phase 2 study, BEHOLD, is a multi-center, randomized, double-masked, sham-controlled study designed to evaluate the safety, tolerability, efficacy and durability of a single 10 mcg dose of UBX1325 in patients with DME. The study enrolled 65 patients who will be followed for up to approximately 48 weeks. More ...

ByUNITY Biotechnology


CD BioGlyco Introduces HMOs Separation Service for Glycobiology Study

CD BioGlyco Introduces HMOs Separation Service for Glycobiology Study

CD BioGlyco, a biotechnology company that provides a full range of glycobiology-related products, analysis, custom synthesis and design to customers worldwide, recently introduced its HMOs separation and analysis services for the healthcare industry. Human milk is the best food for newborns and developing infants, and its unique function is irreplaceable by other dairy ...

ByCD BioGlyco.


Creative Enzymes Probiotics Expands Service Offering with the Launch of Bifidobacterium Strains

Creative Enzymes Probiotics Expands Service Offering with the Launch of Bifidobacterium Strains

The product manager of the Probiotics division is excited to announce the launch of Bifidobacterium strains to support your digestive health and comfort study. Bifidobacterium is a gram-positive, non-motile, usually branching genus of anaerobic bacteria. ...

ByCreative Enzymes


Palisade Bio (NASDAQ: PALI) Adds Pharmaceutical Industry Executive Robert McRae To Leadership Team

Palisade Bio (NASDAQ: PALI) Adds Pharmaceutical Industry Executive Robert McRae To Leadership Team

Prior to joining Viracta, he held positions in both business development and study management for a global clinical research organization. Mr. McRae conducted molecular biology and microbiology research at Wright State University and The United States Air Force Research Laboratory. ...

ByPalisade Bio


Creative Proteomics: GutFlora Omics Platform Launches Virome Sequencing Service to Investigate Gut Microbiota

Creative Proteomics: GutFlora Omics Platform Launches Virome Sequencing Service to Investigate Gut Microbiota

GutFlora Omics Platform recently announced the launch of virome sequencing service to better study gut microbiota. The gut microbiome includes a huge number of bacteria, archaea, fungi, and enteroviruses that colonize the gut. At present, most of the research on gut microbes focuses on the study of bacteria, and with the deepening of research, the number and ...

ByCreative Proteomics


Daxor Corporation Presents New Data Validating the Benefit of the BVA-100 Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100 Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test in identifying heart failure patient-specific phenotypes and detecting true anemia. These data from two separate studies were presented at the American Heart Association (AHA) ...

ByDaxor Corporation


Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

These data underscore the potential of nedosiran to be a meaningful treatment option for those affected by PH1, if approved.” Separately, findings from a real-world study examining de-identified electronic medical record (EMR) data, including demographics, clinical characteristics and healthcare utilization among 47 patients with PH pre- and post-dialysis ...

ByNovo Nordisk A/S


Structural Analysis of Plant Polysaccharides Now Available at CD BioGlyco

Structural Analysis of Plant Polysaccharides Now Available at CD BioGlyco

As an important natural active substance, plant polysaccharides have the advantage of fewer side effects. In recent years, numerous studies have reported that plant-derived active polysaccharides have immunomodulatory, antitumor, antioxidant and hypoglycemic functions. ...

ByCD BioGlyco.


City living attracting young buyers to Melbourne

City living attracting young buyers to Melbourne

"Now buyers have an even better shot at purchasing a home here, and we welcome them with open arms." A separate study carried out by the City of Melbourne found nearly half (46%) of those not living in the city would consider buying or renting there in the future. ...

ByCity of Melbourne


CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced the public availability of preliminary data abstracts from two separate endocarditis studies, including the REMOVE study, to be presented at the upcoming European Association ...

ByCytoSorbents Corporation

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About XPRT Media

XPRT is a global industry marketplace and information resource. Online product catalogs, news, articles, events, publications & more.


  • FAQs
  • Company sitemap
  • Category sitemap
XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
Medical XPRT